The initial order of INVOcell devices was purchased by The National Center for Fertility and Sterility (CENALFES).
The clinical results have demonstrated effectiveness of the INVOcell process without many of the inherent expenses associated with traditional in-vitro fertilization (IVF) procedures.
INVO Bioscience CEO Kathleen Karloff said the company continues to execute on its stated goal of introducing the INVOcell device and process to many of the key opinion leaders throughout the world that will influence expanded acceptance and use of their products.
"CENALFES is one the largest providers of infertility treatments in Bolivia, which we expect to become a strong reference to the exceptional capabilities of INVOcell.
"We look forward to continue working with the many physicians at CENALFES and elsewhere in Bolivia to offer the many suffering infertile patients a cost effective solution to this very unfortunate problem," Karloff said.
INVOcell is registered as a class II device in Bolivia, and therefore according to local laws does not require extended registration and the company continues to market its products in all applicable countries covered by CE mark or other local accepted criteria.
